The Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception

Alzheimer's and Dementia

Volumn 9, Issue 5, 2013, Pages

  Weiner, Michael W ^a,b,c   Veitch, Dallas P ^a   Aisen, Paul S ^d   Beckett, Laurel A ^e   Cairns, Nigel J ^f   Green, Robert C ^g   Harvey, Danielle ^e   Jack, Clifford R ^h   Jagust, William ⁱ   Liu, Enchi ^j   Morris, John C ^d   Petersen, Ronald C ^h   Saykin, Andrew J ^k   Schmidt, Mark E ^l   Shaw, Leslie ^m   Shen, Li ^k   Siuciak, Judith A ⁿ   Soares, Holly ^o   Toga, Arthur W ^p   Trojanowski, John Q ^m  

^a SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g BRIGHAM AND WOMEN S HOSPITAL   (United States)

^h MAYO CLINIC   (United States)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

^j Janssen Alzheimer Immunotherapy   (United States)

^k INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^l JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^m UNIVERSITY OF PENNSYLVANIA   (United States)

ⁿ NATIONAL INSTITUTES OF HEALTH   (United States)

^o BRISTOL MYERS SQUIBB   (United States)

^p UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

Alzheimer's disease; Amyloid; Biomarker; Mild cognitive impairment; Tau

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; AMYLOID BETA PROTEIN; APOLIPOPROTEIN B; APOLIPOPROTEIN E4; BETA SECRETASE 1; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CHOLINESTERASE INHIBITOR; DONEPEZIL; EOTAXIN 3; FLUORODEOXYGLUCOSE F 18; GAMMA INTERFERON; HOMOTAURINE; HYDROCORTISONE; INTERLEUKIN 13; MEMANTINE; NOOTROPIC AGENT; PANCREAS POLYPEPTIDE; PITTSBURGH COMPOUND B; TARENFLURBIL; TAU PROTEIN;

ADL DISABILITY; AGE DISTRIBUTION; AGING; ALGORITHM; ALZHEIMER DISEASE; ASYMPTOMATIC DISEASE; BIOINFORMATICS; BLOOD ANALYSIS; BODY MASS; BRAIN ATROPHY; BRAIN HEMORRHAGE; BRAIN METABOLISM; BRAIN REGION; BRAIN SIZE; BRAIN VENTRICLE; CEREBROSPINAL FLUID EXAMINATION; CLINICAL PROTOCOL; CLU GENE; COGNITIVE RESERVE; CORTICAL THICKNESS (BRAIN); CR1 GENE; DATA ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DIFFERENTIAL DIAGNOSIS; DIFFUSION TENSOR IMAGING; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE SEVERITY; DNA DETERMINATION; DNA SEQUENCE; EARLY DIAGNOSIS; FUNCTIONAL MAGNETIC RESONANCE IMAGING; FUNDING; GENE; GENE LOCUS; GENETIC ASSOCIATION; GENETIC RISK; GLUCOSE METABOLISM; GOLD STANDARD; HETEROZYGOTE; HIPPOCAMPUS; HOMOZYGOTE; HUMAN; IMMUNOASSAY; INTERMETHOD COMPARISON; MILD COGNITIVE IMPAIRMENT; MINI MENTAL STATE EXAMINATION; MORPHOMETRICS; NERVE DEGENERATION; NEUROANATOMY; NEUROBIOLOGY; NEUROIMAGING; NEUROPATHOLOGY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PATHOGENESIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PICALM GENE; POLYPHARMACY; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; PSYCHOLOGICAL RATING SCALE; PUBLICATION; QUALITY CONTROL; QUANTITATIVE TRAIT LOCUS; REVIEW; SAMPLE SIZE; SCREENING TEST; SENSITIVITY AND SPECIFICITY; SINGLE NUCLEOTIDE POLYMORPHISM; STATISTICAL ANALYSIS; SUPPORT VECTOR MACHINE; TEMPORAL LOBE; THREE DIMENSIONAL IMAGING;

ALZHEIMER'S DISEASE; AMYLOID; BIOMARKER; MILD COGNITIVE IMPAIRMENT; TAU;

ALZHEIMER DISEASE; EARLY DIAGNOSIS; HUMANS; MULTICENTER STUDIES AS TOPIC; NEUROIMAGING; UNITED STATES;

EID: 84883552519     PISSN: 15525260     EISSN: 15525279     Source Type: Journal    
DOI: 10.1016/j.jalz.2013.05.1769     Document Type: Review

References (349)

1. J. Hardy Alzheimer's disease: the amyloid cascade hypothesis: an update and reappraisal J Alzheimers Dis 9 Suppl 3 2006 151 153 (Pubitemid 44253307)
2. S.G. Mueller, M.W. Weiner, L.J. Thal, R.C. Petersen, C. Jack, and W. Jagust The Alzheimer's disease neuroimaging initiative, Neuroimaging Clin N Am 15 2005 869 877 xi-xii (Pubitemid 43162384)
3. M.W. Weiner, P.S. Aisen, C.R. Jack Jr., W.J. Jagust, J.Q. Trojanowski, and L. Shaw The Alzheimer's Disease Neuroimaging Initiative: progress report and future plans Alzheimers Dement 6 2010 202.e7-11.e7
4. G.B. Frisoni, and M.W. Weiner Alzheimer's disease neuroimaging initiative special issue Neurobiol Aging 31 2010 1259 1262
5. R.C. Petersen, R.O. Roberts, D.S. Knopman, B.F. Boeve, Y.E. Geda, and R.J. Ivnik Mild cognitive impairment: ten years later Arch Neurol 66 2009 1447 1455
6. A.J. Saykin, L. Shen, T.M. Foroud, S.G. Potkin, S. Swaminathan, and S. Kim Alzheimer's Disease Neuroimaging Initiative biomarkers as quantitative phenotypes: genetics core aims, progress, and plans Alzheimers Dement 6 2010 265 273
7. H. Hampel, Y. Shen, D.M. Walsh, P. Aisen, L.M. Shaw, and H. Zetterberg Biological markers of amyloid beta-related mechanisms in Alzheimer's disease Exp Neurol 223 2010 334 346
8. C.M. Clark, C. Davatzikos, A. Borthakur, A. Newberg, S. Leight, and V.M. Lee Biomarkers for early detection of Alzheimer pathology Neurosignals 16 2008 11 18 (Pubitemid 350308316)
9. A.S. Fleisher, M. Donohue, K. Chen, J.B. Brewer, and P.S. Aisen Applications of neuroimaging to disease-modification trials in Alzheimer's disease Behav Neurol 21 2009 129 136
10. L.M. Shaw, M. Korecka, C.M. Clark, V.M. Lee, and J.Q. Trojanowski Biomarkers of neurodegeneration for diagnosis and monitoring therapeutics Nat Rev Drug Discov 6 2007 295 303 (Pubitemid 46505880)
11. R.C. Petersen, and C.R. Jack Jr. Imaging and biomarkers in early Alzheimer's disease and mild cognitive impairment Clin Pharmacol Ther 86 2009 438 441
12. J.Q. Trojanowski, H. Vandeerstichele, M. Korecka, C.M. Clark, P.S. Aisen, and R.C. Petersen Update on the biomarker core of the Alzheimer's Disease Neuroimaging Initiative subjects Alzheimers Dement 6 2010 230 238
13. J. Hardy, and D.J. Selkoe The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics, Science 297 2002 353 356 (Pubitemid 34790756)
14. C.R. Jack Jr., D.S. Knopman, W.J. Jagust, L.M. Shaw, P.S. Aisen, and M.W. Weiner Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade Lancet Neurol 9 2010 119 128
15. L.M. Shaw PENN biomarker core of the Alzheimer's disease Neuroimaging Initiative Neurosignals 16 2008 19 23 (Pubitemid 350308317)
16. C.R. Jack Jr., V.J. Lowe, S.D. Weigand, H.J. Wiste, M.L. Senjem, and D.S. Knopman Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease Brain 132 (Pt 5) 2009 1355 1365
17. H. Braak, and K. Del Tredici The pathological process underlying Alzheimer's disease in individuals under thirty, Acta Neuropathol 121 2011 171 181
18. B. Dubois, H.H. Feldman, C. Jacova, J.L. Cummings, S.T. Dekosky, and P. Barberger-Gateau Revising the definition of Alzheimer's disease: a new lexicon Lancet Neurol 9 2010 1118 1127
19. R.A. Sperling, P.S. Aisen, L.A. Beckett, D.A. Bennett, S. Craft, and A.M. Fagan Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease Alzheimers Dement 7 2011 280 292
20. R.O. Roberts, Y.E. Geda, D.S. Knopman, R.H. Cha, V.S. Pankratz, and B.F. Boeve The Mayo Clinic Study of Aging: design and sampling, participation, baseline measures and sample characteristics, Neuroepidemiology 30 2008 58 69 (Pubitemid 351311727)
21. R.C. Petersen, R.O. Roberts, D.S. Knopman, Y.E. Geda, R.H. Cha, and V.S. Pankratz Prevalence of mild cognitive impairment is higher in men. The Mayo Clinic Study of Aging, Neurology 75 2010 889 897
22. D. Games, D. Adams, R. Alessandrini, R. Barbour, P. Berthelette, and C. Blackwell Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein Nature 373 1995 523 527
23. R.A. Frank, D. Galasko, H. Hampel, J. Hardy, M.J. de Leon, and P.D. Mehta Biological markers for therapeutic trials in Alzheimer's disease. Proceedings of the biological markers working group; NIA initiative on neuroimaging in Alzheimer's disease Neurobiol Aging 24 2003 521 536 (Pubitemid 36519160)
24. J. Trojanowski Searching for the biomarkers of Alzheimer's Pract Neurol 3 2004 30 34
25. S.G. Mueller, M.W. Weiner, L.J. Thal, R.C. Petersen, C. Jack, and W. Jagust Ways toward an early diagnosis in Alzheimer's disease: the Alzheimer's Disease Neuroimaging Initiative Cogn Dement 5 2006 56 62
26. H. Hampel, K. Burger, S.J. Teipel, A.L. Bokde, H. Zetterberg, and K. Blennow Core candidate neurochemical and imaging biomarkers of Alzheimer's disease Alzheimers Dement 4 2008 38 48
27. W.E. Klunk, H. Engler, A. Nordberg, Y. Wang, G. Blomqvist, and D.P. Holt Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B Ann Neurol 55 2004 306 319 (Pubitemid 38269583)
28. W.E. Klunk, and C.A. Mathis The future of amyloid-beta imaging: a tale of radionuclides and tracer proliferation, Curr Opin Neurol 21 2008 683 687
29. M.P. Kung, C. Hou, Z.P. Zhuang, D. Skovronsky, and H.F. Kung Binding of two potential imaging agents targeting amyloid plaques in postmortem brain tissues of patients with Alzheimer's disease Brain Res 1025 2004 98 105 (Pubitemid 39359172)
30. M.E. Schmidt, E. Siemers, P.J. Snyder, W.Z. Potter, P. Cole, and H. Soares The Alzheimer's Disease Neuroimaging Initiative: perspectives of the Industry Scientific Advisory Board, Alzheimers Dement 6 2010 286 290
31. M.C. Carrillo, C.A. Sanders, and R.G. Katz Maximizing the Alzheimer's Disease Neuroimaging Initiative II Alzheimers Dement 5 2009 271 275
32. A.W. Toga, and K.L. Crawford The informatics core of the Alzheimer's Disease Neuroimaging Initiative, Alzheimers Dement 6 2010 247 256
33. C.R. Jack Jr., M.A. Bernstein, B.J. Borowski, J.L. Gunter, N.C. Fox, and P.M. Thompson Update on the magnetic resonance imaging core of the Alzheimer's disease neuroimaging initiative Alzheimers Dement 6 2010 212 220
34. W.J. Jagust, D. Bandy, K. Chen, N.L. Foster, S.M. Landau, and C.A. Mathis The Alzheimer's Disease Neuroimaging Initiative positron emission tomography core, Alzheimers Dement 6 2010 221 229
35. P.S. Aisen, R.C. Petersen, M.C. Donohue, A. Gamst, R. Raman, and R.G. Thomas Clinical core of the Alzheimer's Disease Neuroimaging Initiative: progress and plans Alzheimers Dement 6 2010 239 246
36. N.J. Cairns, L. Taylor-Reinwald, and J.C. Morris Autopsy consent, brain collection, and standardized neuropathologic assessment of ADNI participants: the essential role of the neuropathology core Alzheimers Dement 6 2010 274 279
37. J.L. Cummings Integrating ADNI results into Alzheimer's disease drug development programs Neurobiol Aging 31 2010 1481 1492
38. S.G. Mueller, M.W. Weiner, L.J. Thal, R.C. Petersen, C.R. Jack, and W. Jagust Ways toward an early diagnosis in Alzheimer's disease: the Alzheimer's Disease Neuroimaging Initiative (ADNI) Alzheimers Dement 1 2005 55 66 (Pubitemid 43348857)
39. R.C. Petersen, and J.Q. Trojanowski Use of Alzheimer disease biomarkers: potentially yes for clinical trials but not yet for clinical practice JAMA 302 2009 436 437
40. R.C. Petersen Early diagnosis of Alzheimer's disease: is MCI too late? Curr Alzheimer Res 6 2009 324 330
41. D. Hill Neuroimaging to assess safety and efficacy of AD therapies Expert Opin Investig Drugs 19 2010 23 26
42. R.E. Becker, and N.H. Greig Alzheimer's disease drug development: old problems require new priorities CNS Neurol Disord Drug Targets 7 2008 499 511
43. M.W. Weiner Editorial: imaging and biomarkers will be used for detection and monitoring progression of early Alzheimer's disease J Nutr Health Aging 13 2009 332
44. K. Ito, B. Corrigan, Q. Zhao, J. French, R. Miller, and H. Soares Disease progression model for cognitive deterioration from Alzheimer's Disease Neuroimaging Initiative database Alzheimers Dement 7 2011 151 160
45. J.L. Gunter, M.A. Bernstein, B.J. Borowski, C.P. Ward, P.J. Britson, and J.P. Felmlee Measurement of MRI scanner performance with the ADNI phantom Med Phys 36 2009 2193 2205
46. F. Kruggel, J. Turner, and L.T. Muftuler Impact of scanner hardware and imaging protocol on image quality and compartment volume precision in the ADNI cohort Neuroimage 49 2010 2123 2133
47. A.J. Ho, X. Hua, S. Lee, A.D. Leow, I. Yanovsky, and B. Gutman Comparing 3 T and 1.5 T MRI for tracking Alzheimer's disease progression with tensor-based morphometry Hum Brain Mapp 31 2010 499 514
48. B. Mortamet, M.A. Bernstein, C.R. Jack Jr., J.L. Gunter, C. Ward, and P.J. Britson Automatic quality assessment in structural brain magnetic resonance imaging Magn Reson Med 62 2009 365 372
49. M.J. Clarkson, S. Ourselin, C. Nielsen, K.K. Leung, J. Barnes, and J.L. Whitwell Comparison of phantom and registration scaling corrections using the ADNI cohort Neuroimage 47 2009 1506 1513
50. C.M. Bauer, H. Jara, and R. Killiany Whole brain quantitative T2 MRI across multiple scanners with dual echo FSE: applications to AD, MCI, and normal aging Neuroimage 52 2010 508 514
51. K.K. Leung, M.J. Clarkson, J.W. Bartlett, S. Clegg, C.R. Jack Jr., and M.W. Weiner Robust atrophy rate measurement in Alzheimer's disease using multi-site serial MRI: tissue-specific intensity normalization and parameter selection Neuroimage 50 2010 516 523
52. C.R. Jack Jr., M.A. Bernstein, N.C. Fox, P. Thompson, G. Alexander, and D. Harvey The Alzheimer's Disease Neuroimaging Initiative (ADNI): MRI methods, J Magn Reson Imaging 27 2008 685 691 (Pubitemid 351508080)
53. R.G. Boyes, J.L. Gunter, C. Frost, A.L. Janke, T. Yeatman, and D.L. Hill Intensity non-uniformity correction using N3 on 3-T scanners with multichannel phased array coils Neuroimage 39 2008 1752 1762
54. A.D. Leow, A.D. Klunder, C.R. Jack Jr., A.W. Toga, A.M. Dale, and M.A. Bernstein Longitudinal stability of MRI for mapping brain change using tensor-based morphometry Neuroimage 31 2006 627 640 (Pubitemid 44218807)
55. A. Joshi, R.A. Koeppe, and J.A. Fessler Reducing between scanner differences in multi-center PET studies Neuroimage 46 2009 154 159
56. L.M. Shaw, H. Vanderstichele, M. Knapik-Czajka, M. Figurski, E. Coart, and K. Blennow Qualification of the analytical and clinical performance of CSF biomarker analyses in ADNI Acta Neuropathol 121 2011 597 609
57. L.M. Shaw, H. Vanderstichele, M. Knapik-Czajka, C.M. Clark, P.S. Aisen, and R.C. Petersen Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects Ann Neurol 65 2009 403 413
58. K.K. Leung, J. Barnes, M. Modat, G.R. Ridgway, J.W. Bartlett, and N.C. Fox Brain MAPS: an automated, accurate and robust brain extraction technique using a template library Neuroimage 55 2011 1091 1108
59. K.K. Leung, J. Barnes, G.R. Ridgway, J.W. Bartlett, M.J. Clarkson, and K. Macdonald Automated cross-sectional and longitudinal hippocampal volume measurement in mild cognitive impairment and Alzheimer's disease Neuroimage 51 2010 1345 1359
60. R. Wolz, P. Aljabar, J.V. Hajnal, A. Hammers, and D. Rueckert LEAP: learning embeddings for atlas propagation Neuroimage 49 2010 1316 1325
61. J.M. Lotjonen, R. Wolz, J.R. Koikkalainen, L. Thurfjell, G. Waldemar, and H. Soininen Fast and robust multi-atlas segmentation of brain magnetic resonance images Neuroimage 49 2010 2352 2365
62. R.A. Heckemann, S. Keihaninejad, P. Aljabar, D. Rueckert, J.V. Hajnal, and A. Hammers Improving intersubject image registration using tissue-class information benefits robustness and accuracy of multi-atlas based anatomical segmentation Neuroimage 51 2010 221 227
63. J.H. Morra, Z. Tu, L.G. Apostolova, A.E. Green, C. Avedissian, and S.K. Madsen Validation of a fully automated 3D hippocampal segmentation method using subjects with Alzheimer's disease mild cognitive impairment, and elderly controls Neuroimage 43 2008 59 68
64. R. Wolz, R.A. Heckemann, P. Aljabar, J.V. Hajnal, A. Hammers, and J. Lotjonen Measurement of hippocampal atrophy using 4D graph-cut segmentation: application to ADNI Neuroimage 52 2010 109 118
65. S. Huang, J. Li, L. Sun, J. Ye, A. Fleisher, and T. Wu Learning brain connectivity of Alzheimer's disease by sparse inverse covariance estimation Neuroimage 50 2010 935 949
66. P. Calvini, A. Chincarini, G. Gemme, M.A. Penco, S. Squarcia, and F. Nobili Automatic analysis of medial temporal lobe atrophy from structural MRIs for the early assessment of Alzheimer disease Med Phys 36 2009 3737 3747
67. D. Holland, and A.M. Dale Nonlinear registration of longitudinal images and measurement of change in regions of interest Med Image Anal 15 2011 489 497
68. M. Chupin, E. Gerardin, R. Cuingnet, C. Boutet, L. Lemieux, and S. Lehericy Fully automatic hippocampus segmentation and classification in Alzheimer's disease and mild cognitive impairment applied on data from ADNI Hippocampus 19 2009 579 587
69. J.H. Morra, Z. Tu, L.G. Apostolova, A.E. Green, C. Avedissian, and S.K. Madsen Automated 3D mapping of hippocampal atrophy and its clinical correlates in 400 subjects with Alzheimer's disease, mild cognitive impairment, and elderly controls Hum Brain Mapp 30 2009 2766 2788
70. H. Wang, S. Das, J. Pluta, C. Craige, M. Altinay, and B. Avants Standing on the shoulders of giants: improving medical image segmentation via bias correction Med Image Comput Comput Assist Interv 13 Pt 3 2010 105 112
71. M. Bossa, E. Zacur, and S. Olmos Statistical analysis of relative pose information of subcortical nuclei: application on ADNI data Neuroimage 55 2011 999 1008
72. M. Bossa, E. Zacur, and S. Olmos Tensor-based morphometry with stationary velocity field diffeomorphic registration: application to ADNI Neuroimage 51 2010 956 969
73. X. Hua, A.D. Leow, S. Lee, A.D. Klunder, A.W. Toga, and N. Lepore 3D characterization of brain atrophy in Alzheimer's disease and mild cognitive impairment using tensor-based morphometry Neuroimage 41 2008 19 34
74. P.A. Yushkevich, B.B. Avants, S.R. Das, J. Pluta, M. Altinay, and C. Craige Bias in estimation of hippocampal atrophy using deformation-based morphometry arises from asymmetric global normalization: an illustration in ADNI 3 T MRI data Neuroimage 50 2010 434 445
75. H. Park, and J. Seo Application of multidimensional scaling to quantify shape in Alzheimer's disease and its correlation with Mini Mental State Examination: a feasibility study J Neurosci Methods 194 2011 380 385
76. W. Chen, X. Song, Y. Zhang, S. Darvesh, N. Zhang, and R.C. D'Arcy An MRI-based semiquantitative index for the evaluation of brain atrophy and lesions in Alzheimer's disease, mild cognitive impairment and normal aging Dement Geriatr Cogn Disord 30 2010 121 130
77. O. Acosta, P. Bourgeat, M.A. Zuluaga, J. Fripp, O. Salvado, and S. Ourselin Automated voxel-based 3D cortical thickness measurement in a combined Lagrangian-Eulerian PDE approach using partial volume maps Med Image Anal 13 2009 730 743
78. R.D. King, A.T. George, T. Jeon, L.S. Hynan, T.S. Youn, and D.N. Kennedy Characterization of atrophic changes in the cerebral cortex using fractal dimensional analysis Brain Imaging Behav 3 2009 154 166
79. R.D. King, B. Brown, M. Hwang, T. Jeon, and A.T. George Fractal dimension analysis of the cortical ribbon in mild Alzheimer's disease Neuroimage 53 2010 471 479
80. Y. Li, Y. Wang, Z. Xue, F. Shi, W. Lin, and D. Shen Consistent 4D cortical thickness measurement for longitudinal neuroimaging study Med Image Comput Comput Assist Interv 13 Pt 2 2010 133 142
81. L. Risser, F.X. Vialard, R. Wolz, D.D. Holm, and D. Rueckert Simultaneous fine and coarse diffeomorphic registration: application to atrophy measurement in Alzheimer's disease Med Image Comput Comput Assist Interv 13 Pt 2 2010 610 617
82. T. Zhang, and C. Davatzikos ODVBA: Optimally-Discriminative Voxel-Based Analysis IEEE Trans Med Imaging 30 2011 1441 1454
83. Y. Fan, N. Batmanghelich, C.M. Clark, and C. Davatzikos Spatial patterns of brain atrophy in MCI patients, identified via high-dimensional pattern classification, predict subsequent cognitive decline Neuroimage 39 2008 1731 1743 (Pubitemid 351179414)
84. C. Haense, K. Herholz, W.J. Jagust, and W.D. Heiss Performance of FDG PET for detection of Alzheimer's disease in two independent multicentre samples (NEST-DD and ADNI) Dement Geriatr Cogn Disord 28 2009 259 266
85. K. Chen, N. Ayutyanont, J.B. Langbaum, A.S. Fleisher, C. Reschke, and W. Lee Characterizing Alzheimer's disease using a hypometabolic convergence index Neuroimage 56 2011 52 60
86. O. Kohannim, X. Hua, D.P. Hibar, S. Lee, Y.Y. Chou, and A.W. Toga Boosting power for clinical trials using classifiers based on multiple biomarkers Neurobiol Aging 31 2010 1429 1442
87. B. Lemoine, S. Rayburn, and R. Benton Data fusion and feature selection for Alzheimer's disease Lect Notes Comput Sci 6334 2010 320 327
88. C. Hinrichs, V. Singh, L. Mukherjee, G. Xu, M.K. Chung, and S.C. Johnson Spatially augmented LPboosting for AD classification with evaluations on the ADNI dataset Neuroimage 48 2009 138 149
89. L. Shen, Y. Qi, S. Kim, K. Nho, J. Wan, and S.L. Risacher Sparse bayesian learning for identifying imaging biomarkers in AD prediction Med Image Comput Comput Assist Interv 13 Pt 3 2010 611 618
90. D. Salas-Gonzalez, J.M. Gorriz, J. Ramirez, I.A. Illan, M. Lopez, and F. Segovia Feature selection using factor analysis for Alzheimer's diagnosis using 18F-FDG PET images Med Phys 37 2010 6084 6095
91. C.M. Stonnington, C. Chu, S. Kloppel, C.R. Jack Jr., J. Ashburner, and R.S. Frackowiak Predicting clinical scores from magnetic resonance scans in Alzheimer's disease Neuroimage 51 2010 511 517
92. K. Franke, G. Ziegler, S. Kloppel, and C. Gaser Estimating the age of healthy subjects from T1-weighted MRI scans using kernel methods: exploring the influence of various parameters Neuroimage 50 2010 883 892
93. R. Filipovych, and C. Davatzikos Semi-supervised pattern classification of medical images: application to mild cognitive impairment (MCI) Neuroimage 55 2011 1109 1119
94. W. Yang, C.X. Hong, H. Xie, and X. Huang ICA-based automatic classification of magnetic resonance images from ADNI data Lect Notes Comput Sci 6330 2010 340 347
95. M. Pelaez-Coca, M. Bossa, and S. Olmos Discrimination of AD and normal subjects from MRI: anatomical versus statistical regions Neurosci Lett 487 2011 113 117
96. D.A. Llano, G. Laforet, and V. Devanarayan Derivation of a new ADAS-cog composite using tree-based multivariate analysis: prediction of conversion from mild cognitive impairment to Alzheimer disease Alzheimer Dis Assoc Disord 25 2010 73 84
97. F. Rousseau A non-local approach for image super-resolution using intermodality priors, Med Image Anal 14 2010 594 605
98. S. Gerber, T. Tasdizen, P. Thomas Fletcher, S. Joshi, and R. Whitaker Manifold modeling for brain population analysis Med Image Anal 14 2010 643 653
99. C. Habeck, and Y. Stern Multivariate data analysis for neuroimaging data: overview and application to Alzheimer's disease Cell Biochem Biophys 58 2010 53 67
100. C.G. Habeck Basics of multivariate analysis in neuroimaging data J Vis Exp 2010 41 pii: 1988
101. X. Wu, K. Chen, L. Yao, N. Ayutyanont, J.B. Langbaum, and A. Fleisher Assessing the reliability to detect cerebral hypometabolism in probable Alzheimer's disease and amnestic mild cognitive impairment J Neurosci Methods 192 2010 277 285
102. N. Singh, P.T. Fletcher, J.S. Preston, L. Ha, R. King, and J.S. Marron Multivariate statistical analysis of deformation momenta relating anatomical shape to neuropsychological measures Med Image Comput Comput Assist Interv 13 Pt 3 2010 529 537
103. M. Vounou, T.E. Nichols, and G. Montana Discovering genetic associations with high-dimensional neuroimaging phenotypes: a sparse reduced-rank regression approach Neuroimage 53 2010 1147 1159
104. K. Chen, J.B. Langbaum, A.S. Fleisher, N. Ayutyanont, C. Reschke, and W. Lee Twelve-month metabolic declines in probable Alzheimer's disease and amnestic mild cognitive impairment assessed using an empirically pre-defined statistical region-of-interest: findings from the Alzheimer's Disease Neuroimaging Initiative Neuroimage 51 2010 654 664
105. M. Silver, G. Montana, and T.E. Nichols False positives in neuroimaging genetics using voxel-based morphometry data Neuroimage 54 2011 992 1000
106. R.C. Petersen, P.S. Aisen, L.A. Beckett, M.C. Donohue, A.C. Gamst, and D.J. Harvey Alzheimer's Disease Neuroimaging Initiative (ADNI): clinical characterization Neurology 74 2010 201 209
107. N.U. Epstein, A.J. Saykin, S.L. Risacher, S. Gao, and M.R. Farlow Differences in medication use in the Alzheimer's disease neuroimaging initiative: analysis of baseline characteristics Drugs Aging 27 2010 677 686
108. L.S. Schneider, P.S. Insel, and M.W. Weiner Treatment with cholinesterase inhibitors and memantine of patients in the Alzheimer's Disease Neuroimaging Initiative Arch Neurol 68 2011 58 66
109. C. Fennema-Notestine, D.J. Hagler Jr., L.K. McEvoy, A.S. Fleisher, E.H. Wu, and D.S. Karow Structural MRI biomarkers for preclinical and mild Alzheimer's disease Hum Brain Mapp 30 2009 3238 3253
110. D.S. Karow, L.K. McEvoy, C. Fennema-Notestine, D.J. Hagler Jr., R.G. Jennings, and J.B. Brewer Relative capability of MR imaging and FDG PET to depict changes associated with prodromal and early Alzheimer disease Radiology 256 2010 932 942
111. C.R. McDonald, L.K. McEvoy, L. Gharapetian, C. Fennema-Notestine, D.J. Hagler Jr., and D. Holland Regional rates of neocortical atrophy from normal aging to early Alzheimer disease Neurology 73 2009 457 465
112. X. Hua, A.D. Leow, N. Parikshak, S. Lee, M.C. Chiang, and A.W. Toga Tensor-based morphometry as a neuroimaging biomarker for Alzheimer's disease: an MRI study of 676 AD, MCI, and normal subjects Neuroimage 43 2008 458 469
113. A.D. Leow, I. Yanovsky, N. Parikshak, X. Hua, S. Lee, and A.W. Toga Alzheimer's disease neuroimaging initiative: a one-year follow up study using tensor-based morphometry correlating degenerative rates, biomarkers and cognition Neuroimage 45 2009 645 655
114. S.L. Risacher, A.J. Saykin, J.D. West, L. Shen, H.A. Firpi, and B.C. McDonald Baseline MRI predictors of conversion from MCI to probable AD in the ADNI cohort Curr Alzheimer Res 6 2009 347 361
115. S.L. Risacher, L. Shen, J.D. West, S. Kim, B.C. McDonald, and L.A. Beckett Longitudinal MRI atrophy biomarkers: relationship to conversion in the ADNI cohort Neurobiol Aging 31 2010 1401 1418
116. Schuff N, Tosun D, Insel PS, Chiang GC, Truran D, Aisen PS, et al. Nonlinear time course of brain volume loss in cognitively normal and impaired elders. Neurobiol Aging (in press).
117. L.K. McEvoy, C. Fennema-Notestine, J.C. Roddey, D.J. Hagler Jr., D. Holland, and D.S. Karow Alzheimer disease: quantitative structural neuroimaging for detection and prediction of clinical and structural changes in mild cognitive impairment Radiology 251 2009 195 205
118. C. Misra, Y. Fan, and C. Davatzikos Baseline and longitudinal patterns of brain atrophy in MCI patients, and their use in prediction of short-term conversion to AD: results from ADNI Neuroimage 44 2009 1415 1422
119. Davatzikos C, Bhatt P, Shaw LM, Batmanghelich KN, Trojanowski JQ. Prediction of MCI to AD conversion, via MRI, CSF biomarkers, and pattern classification. Neurobiol Aging (in press).
120. X. Hua, D.P. Hibar, S. Lee, A.W. Toga, C.R. Jack Jr., and M.W. Weiner Sex and age differences in atrophic rates: an ADNI study with n=1368 MRI scans Neurobiol Aging 31 2010 1463 1480
121. N. Schuff, N. Woerner, L. Boreta, T. Kornfield, L.M. Shaw, and J.Q. Trojanowski MRI of hippocampal volume loss in early Alzheimer's disease in relation to ApoE genotype and biomarkers Brain 132 (Pt 4) 2009 1067 1077
122. A. Qiu, C. Fennema-Notestine, A.M. Dale, and M.I. Miller Regional shape abnormalities in mild cognitive impairment and Alzheimer's disease Neuroimage 45 2009 656 661
123. L.G. Apostolova, J.H. Morra, A.E. Green, K.S. Hwang, C. Avedissian, and E. Woo Automated 3D mapping of baseline and 12-month associations between three verbal memory measures and hippocampal atrophy in 490 ADNI subjects Neuroimage 51 2010 488 499
124. J.H. Morra, Z. Tu, L.G. Apostolova, A.E. Green, C. Avedissian, and S.K. Madsen Automated mapping of hippocampal atrophy in 1-year repeat MRI data from 490 subjects with Alzheimer's disease, mild cognitive impairment, and elderly controls Neuroimage 45 Suppl 1 2009 S3 S15
125. M.C. Evans, J. Barnes, C. Nielsen, L.G. Kim, S.L. Clegg, and M. Blair Volume changes in Alzheimer's disease and mild cognitive impairment: cognitive associations Eur Radiol 20 2010 674 682
126. Y.Y. Chou, N. Lepore, C. Avedissian, S.K. Madsen, N. Parikshak, and X. Hua Mapping correlations between ventricular expansion and CSF amyloid and tau biomarkers in 240 subjects with Alzheimer's disease, mild cognitive impairment and elderly controls Neuroimage 46 2009 394 410
127. Y.Y. Chou, N. Lepore, P. Saharan, S.K. Madsen, X. Hua, and C.R. Jack Ventricular maps in 804 ADNI subjects: correlations with CSF biomarkers and clinical decline Neurobiol Aging 31 2010 1386 1400
128. P. Vemuri, H.J. Wiste, S.D. Weigand, D.S. Knopman, L.M. Shaw, and J.Q. Trojanowski Effect of apolipoprotein E on biomarkers of amyloid load and neuronal pathology in Alzheimer disease Ann Neurol 67 2010 308 316
129. Andrawis JP, Hwang KS, Green AE, Kotlerman J, Elashoff D, Morra JH, et al. Effects of ApoE4 and maternal history of dementia on hippocampal atrophy. Neurobiol Aging (in press).
130. S.K. Madsen, J. Ho, X. Hua, P.S. Saharan, A.W. Toga, and C.R. Jack Jr. 3D maps localize caudate nucleus atrophy in 400 Alzheimer's disease, mild cognitive impairment, and healthy elderly subjects Neurobiol Aging 31 2010 1312 1325
131. S.J. Greene, and R.J. Killiany Subregions of the inferior parietal lobule are affected in the progression to Alzheimer's disease Neurobiol Aging 31 2010 1304 1311
132. P. Vemuri, H.J. Wiste, S.D. Weigand, L.M. Shaw, J.Q. Trojanowski, and M.W. Weiner MRI and CSF biomarkers in normal, MCI, and AD subjects: diagnostic discrimination and cognitive correlations Neurology 73 2009 287 293
133. A.J. Ho, C.A. Raji, J.T. Becker, O.L. Lopez, L.H. Kuller, and X. Hua Obesity is linked with lower brain volume in 700 AD and MCI patients Neurobiol Aging 31 2010 1326 1339
134. J.B. Langbaum, K. Chen, W. Lee, C. Reschke, D. Bandy, and A.S. Fleisher Categorical and correlational analyses of baseline fluorodeoxyglucose positron emission tomography images from the Alzheimer's Disease Neuroimaging Initiative (ADNI) Neuroimage 45 2009 1107 1116
135. S.M. Landau, D. Harvey, C.M. Madison, R.A. Koeppe, E.M. Reiman, and N.L. Foster Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI Neuro0biol Aging 32 2011 1207 1218
136. K.B. Walhovd, A.M. Fjell, A.M. Dale, L.K. McEvoy, J. Brewer, and D.S. Karow Multi-modal imaging predicts memory performance in normal aging and cognitive decline Neurobiol Aging 31 2010 1107 1121
137. D.A. Wolk, and B.C. Dickerson Fractionating verbal episodic memory in Alzheimer's disease Neuroimage 54 2011 1530 1539
138. Y.L. Chang, M.W. Bondi, C. Fennema-Notestine, L.K. McEvoy, D.J. Hagler Jr., and M.W. Jacobson Brain substrates of learning and retention in mild cognitive impairment diagnosis and progression to Alzheimer's disease Neuropsychologia 48 2010 1237 1247
139. B.C. Dickerson, and D.A. Wolk Dysexecutive versus amnesic phenotypes of very mild Alzheimer's disease are associated with distinct clinical, genetic and cortical thinning characteristics J Neurol Neurosurg Psychiatry 82 2011 45 51
140. Y.L. Chang, M.W. Jacobson, C. Fennema-Notestine, D.J. Hagler Jr., R.G. Jennings, and A.M. Dale Level of executive function influences verbal memory in amnestic mild cognitive impairment and predicts prefrontal and posterior cingulate thickness Cereb Cortex 20 2010 1305 1313
141. D.A. Wolk, B.C. Dickerson, M. Weiner, M. Aiello, P. Aisen, and M.S. Albert Apolipoprotein E (APOE) genotype has dissociable effects on memory and attentional-executive network function in Alzheimer's disease Proc Natl Acad Sci USA 107 2010 10256 10261
142. McDonald CR, Gharapetian L, McEvoy LK, Fennema-Notestine C, Hagler DJ Jr, Holland D, et al. Relationship between regional atrophy rates and cognitive decline in mild cognitive impairment. Neurobiol Aging (in press).
143. O.C. Okonkwo, M.L. Alosco, B.A. Jerskey, L.H. Sweet, B.R. Ott, and G. Tremont Cerebral atrophy, apolipoprotein E varepsilon4, and rate of decline in everyday function among patients with amnestic mild cognitive impairment Alzheimers Dement 6 2010 404 411
144. O.C. Okonkwo, M.L. Alosco, H.R. Griffith, M.M. Mielke, L.M. Shaw, and J.Q. Trojanowski Cerebrospinal fluid abnormalities and rate of decline in everyday function across the dementia spectrum: normal aging, mild cognitive impairment, and Alzheimer disease Arch Neurol 67 2010 688 696
145. B.B. Cronk, D.K. Johnson, and J.M. Burns Body mass index and cognitive decline in mild cognitive impairment Alzheimer Dis Assoc Disord 24 2010 126 130
146. D. Tosun, N. Schuff, D. Truran-Sacrey, L.M. Shaw, J.Q. Trojanowski, and P. Aisen Relations between brain tissue loss, CSF biomarkers, and the ApoE genetic profile: a longitudinal MRI study Neurobiol Aging 31 2010 1340 1354
147. A.M. Fjell, K.B. Walhovd, C. Fennema-Notestine, L.K. McEvoy, D.J. Hagler, and D. Holland CSF biomarkers in prediction of cerebral and clinical change in
148. B.R. Ott, R.A. Cohen, A. Gongvatana, O.C. Okonkwo, C.E. Johanson, and E.G. Stopa Brain ventricular volume and cerebrospinal fluid biomarkers of Alzheimer's disease J Alzheimers Dis 20 2010 647 657
149. S. Kim, S. Swaminathan, L. Shen, S.L. Risacher, K. Nho, and T. Foroud Genome-wide association study of CSF biomarkers Abeta1-42, t-tau, and p-tau181p in the ADNI cohort Neurology 76 2011 69 79
150. W.J. Jagust, S.M. Landau, L.M. Shaw, J.Q. Trojanowski, R.A. Koeppe, and E.M. Reiman Relationships between biomarkers in aging and dementia Neurology 73 2009 1193 1199
151. L.G. Apostolova, K.S. Hwang, J.P. Andrawis, A.E. Green, S. Babakchanian, and J.H. Morra 3D PIB and CSF biomarker associations with hippocampal atrophy in ADNI subjects Neurobiol Aging 31 2010 1284 1303
152. C.R. Jack Jr., H.J. Wiste, P. Vemuri, S.D. Weigand, M.L. Senjem, and G. Zeng Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease Brain 133 2010 3336 3348
153. A. Caroli, and G.B. Frisoni The dynamics of Alzheimer's disease biomarkers in the Alzheimer's Disease Neuroimaging Initiative cohort, Neurobiol Aging 31 2010 1263 1274
154. L.A. Beckett, D.J. Harvey, A. Gamst, M. Donohue, J. Kornak, and H. Zhang The Alzheimer's Disease Neuroimaging Initiative: annual change in biomarkers and clinical outcomes, Alzheimers Dement 6 2010 257 264
155. K.B. Walhovd, A.M. Fjell, J. Brewer, L.K. McEvoy, C. Fennema-Notestine, and D.J. Hagler Jr. Combining MR imaging, positron-emission tomography, and CSF biomarkers in the diagnosis and prognosis of Alzheimer disease Am J Neuroradiol 31 2010 347 354
156. P. Vemuri, H.J. Wiste, S.D. Weigand, D.S. Knopman, J.Q. Trojanowski, and L.M. Shaw Serial MRI and CSF biomarkers in normal aging, MCI, and AD Neurology 75 2010 143 151
157. Li Y, Wang Y, Wu G, Shi F, Zhou L, Lin W, et al. Discriminant analysis of longitudinal cortical thickness changes in Alzheimer's disease using dynamic and network features. Neurobiol Aging (in press).
158. R. Cuingnet, E. Gerardin, J. Tessieras, G. Auzias, S. Lehericy, and M.O. Habert Automatic classification of patients with Alzheimer's disease from structural MRI: a comparison of ten methods using the ADNI database Neuroimage 56 2010 766 781
159. G. De Meyer, F. Shapiro, H. Vanderstichele, E. Vanmechelen, S. Engelborghs, and P.P. De Deyn Diagnosis-independent alzheimer disease biomarker signature in cognitively normal elderly people Arch Neurol 67 2010 949 956
160. J.M. Schott, J.W. Bartlett, N.C. Fox, and J. Barnes Increased brain atrophy rates in cognitively normal older adults with low cerebrospinal fluid Abeta1-42 Ann Neurol 68 2010 825 834
161. Ewers M, Walsh C, Trojanowski JQ, Shaw LM, Petersen RC, Jack CR Jr, et al. Prediction of conversion from mild cognitive impairment to Alzheimer's disease dementia based upon biomarkers and neuropsychological test performance. Neurobiol Aging (in press).
162. M. van Gils, J. Koikkalainen, J. Mattila, S. Herukka, J. Lotjonen, and H. Soininen Discovery and use of efficient biomarkers for objective disease state assessment in Alzheimer's disease Conf Proc IEEE Eng Med Biol Soc 2010 2010 2886 2889
163. R.S. Desikan, H.J. Cabral, F. Settecase, C.P. Hess, W.P. Dillon, and C.M. Glastonbury Automated MRI measures predict progression to Alzheimer's disease Neurobiol Aging 31 2010 1364 1374
164. S. Kovacevic, M.S. Rafii, and J.B. Brewer High-throughput, fully automated volumetry for prediction of MMSE and CDR decline in mild cognitive impairment Alzheimer Dis Assoc Disord 23 2009 139 145
165. O. Querbes, F. Aubry, J. Pariente, J.A. Lotterie, J.F. Demonet, and V. Duret Early diagnosis of Alzheimer's disease using cortical thickness: impact of cognitive reserve Brain 132 2009 2036 2047
166. O. Carmichael, C. Schwarz, D. Drucker, E. Fletcher, D. Harvey, and L. Beckett Longitudinal changes in white matter disease and cognition in the first year of the Alzheimer disease neuroimaging initiative Arch Neurol 67 2010 1370 1378
167. P. Vemuri, H.J. Wiste, S.D. Weigand, L.M. Shaw, J.Q. Trojanowski, and M.W. Weiner MRI and CSF biomarkers in normal, MCI, and AD subjects: predicting future clinical change Neurology 73 2009 294 301
168. L.K. McEvoy, S.D. Edland, D. Holland, D.J. Hagler, J.C. Roddey, and C. Fennema-Notestine Neuroimaging enrichment strategy for secondary prevention trials in Alzheimer disease Alzheimer Dis Assoc Disord 24 2010 269 277
169. S.D. Weigand, P. Vemuri, H.J. Wiste, M.L. Senjem, V.S. Pankratz, and P.S. Aisen Transforming cerebrospinal fluid Abeta42 measures into calculated Pittsburgh Compound B units of brain Abeta amyloid Alzheimers Dement 7 2011 133 141
170. L.S. Schneider, R.E. Kennedy, and G.R. Cutter Requiring an amyloid-beta1-42 biomarker for prodromal Alzheimer's disease or mild cognitive impairment does not lead to more efficient clinical trials Alzheimers Dement 6 2010 367 377
171. K. Ito, S. Ahadieh, B. Corrigan, J. French, T. Fullerton, and T. Tensfeldt Disease progression meta-analysis model in Alzheimer's disease Alzheimers Dement 6 2010 39 53
172. M. Lorenzi, M. Donohue, D. Paternico, C. Scarpazza, S. Ostrowitzki, and O. Blin Enrichment through biomarkers in clinical trials of Alzheimer's drugs in patients with mild cognitive impairment Neurobiol Aging 13 2010 1443.e1-51.e1
173. S.M. Landau, D. Harvey, C.M. Madison, E.M. Reiman, N.L. Foster, and P.S. Aisen Comparing predictors of conversion and decline in mild cognitive impairment Neurology 75 2010 230 238
174. J.M. Schott, J.W. Bartlett, J. Barnes, K.K. Leung, S. Ourselin, and N.C. Fox Reduced sample sizes for atrophy outcomes in Alzheimer's disease trials: baseline adjustment Neurobiol Aging 31 2010 1452.e2-62.e2
175. S.M. Nestor, R. Rupsingh, M. Borrie, M. Smith, V. Accomazzi, and J.L. Wells Ventricular enlargement as a possible measure of Alzheimer's disease progression validated using the Alzheimer's disease neuroimaging initiative database Brain 131 (Pt 9) 2008 2443 2454
176. D. Holland, J.B. Brewer, D.J. Hagler, C. Fenema-Notestine, A.M. Dale, and M. Weiner Subregional neuroanatomical change as a biomarker for Alzheimer's disease Proc Natl Acad Sci USA 106 2009 20954 20959
177. X. Hua, S. Lee, I. Yanovsky, A.D. Leow, Y.Y. Chou, and A.J. Ho Optimizing power to track brain degeneration in Alzheimer's disease and mild cognitive impairment with tensor-based morphometry: an ADNI study of 515 subjects Neuroimage 48 2009 668 681
178. X. Hua, B. Gutman, C.P. Boyle, P. Rajagopalan, A.D. Leow, and I. Yanovsky Accurate measurement of brain changes in longitudinal MRI scans using tensor-based morphometry Neuroimage 57 2011 5 14
179. M. Gatz, C.A. Reynolds, L. Fratiglioni, B. Johansson, J.A. Mortimer, and S. Berg Role of genes and environments for explaining Alzheimer disease Arch Gen Psychiatry 63 2006 168 174 (Pubitemid 43213878)
180. J.W. Ashford, and J.A. Mortimer Non-familial Alzheimer's disease is mainly due to genetic factors J Alzheimers Dis 4 2002 169 177 (Pubitemid 35006049)
181. J.C. Lambert, S. Heath, G. Even, D. Campion, K. Sleegers, and M. Hiltunen Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease Nat Genet 41 2009 1094 1099
182. D. Harold, R. Abraham, P. Hollingworth, R. Sims, A. Gerrish, and M.L. Hamshere Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease Nat Genet 41 2009 1088 1093
183. M.M. Carrasquillo, O. Belbin, T.A. Hunter, L. Ma, G.D. Bisceglio, and F. Zou Replication of CLU, CR1, and PICALM associations with alzheimer disease Arch Neurol 67 2010 961 964
184. S.G. Potkin, G. Guffanti, A. Lakatos, J.A. Turner, F. Kruggel, and J.H. Fallon Hippocampal atrophy as a quantitative trait in a genome-wide association study identifying novel susceptibility genes for Alzheimer's disease PLoS One 4 2009 e6501
185. G. Jun, A.C. Naj, G.W. Beecham, L.S. Wang, J. Buros, and P.J. Gallins Meta-analysis confirms CR1, CLU, and PICALM as Alzheimer disease risk loci and reveals interactions with APOE genotypes Arch Neurol 67 2010 1473 1484
186. A.C. Naj, G. Jun, G.W. Beecham, L.S. Wang, B.N. Vardarajan, and J. Buros Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease Nat Genet 43 2011 436 441
187. P. Hollingworth, D. Harold, R. Sims, A. Gerrish, J.C. Lambert, and M.M. Carrasquillo Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease Nat Genet 43 2011 429 435
188. A. Lakatos, O. Derbeneva, D. Younes, D. Keator, T. Bakken, and M. Lvova Association between mitochondrial DNA variations and Alzheimer's disease in the ADNI cohort Neurobiol Aging 31 2010 1355 1363
189. J.S. Kauwe, S. Bertelsen, K. Mayo, C. Cruchaga, R. Abraham, and P. Hollingworth Suggestive synergy between genetic variants in TF and HFE as risk factors for Alzheimer's disease Am J Med Genet B Neuropsychiatr Genet 153B 2010 955 959
190. C. Cruchaga, S. Bertelsen, J.S. Kauwe, P. Nowotny, and A.R. Shah SNPs in the regulatory subunit of calcineurin are associated with CSF tau protein levels, brain mRNA levels Alzheimers Dement 5 Suppl 4 2009 P471 P472
191. C. Cruchaga, J.S. Kauwe, K. Mayo, N. Spiegel, S. Bertelsen, and P. Nowotny SNPs associated with cerebrospinal fluid phospho-tau levels influence rate of decline in Alzheimer's disease PLoS Genet 2010 6 pii: e1001101
192. J.S. Kauwe, C. Cruchaga, S. Bertelsen, K. Mayo, W. Latu, and P. Nowotny Validating predicted biological effects of Alzheimer's disease associated SNPs using CSF biomarker levels J Alzheimers Dis 21 2010 833 842
193. A. Biffi, C.D. Anderson, R.S. Desikan, M. Sabuncu, L. Cortellini, and N. Schmansky Genetic variation and neuroimaging measures in Alzheimer disease Arch Neurol 67 2010 677 685
194. L. Shen, S. Kim, S.L. Risacher, K. Nho, S. Swaminathan, and J.D. West Whole genome association study of brain-wide imaging phenotypes for identifying quantitative trait loci in MCI and AD: a study of the ADNI cohort Neuroimage 53 2010 1051 1063
195. J.L. Stein, X. Hua, S. Lee, A.J. Ho, A.D. Leow, and A.W. Toga Voxelwise genome-wide association study (vGWAS) Neuroimage 53 2010 1160 1174
196. J.L. Stein, X. Hua, J.H. Morra, S. Lee, D.P. Hibar, and A.J. Ho Genome-wide analysis reveals novel genes influencing temporal lobe structure with relevance to neurodegeneration in Alzheimer's disease Neuroimage 51 2010 542 554
197. Furney SJ, Simmons A, Breen G, Pedroso I, Lunnon K, Proitsi P, et al. Genome-wide association with MRI atrophy measures as a quantitative trait locus for Alzheimer's disease. Mol Psychiatry (in press).
198. L. Bertram, and H. Heekeren Obesity and the brain: a possible genetic link Alzheimers Res Ther 2 2010 27
199. M.R. Han, G.D. Schellenberg, and L.S. Wang Genome-wide association reveals genetic effects on human Abeta42 and tau protein levels in cerebrospinal fluids: a case control study BMC Neurol 10 2010 90
200. A.M. Fjell, K.B. Walhovd, C. Fennema-Notestine, L.K. McEvoy, D.J. Hagler, and D. Holland One-year brain atrophy evident in healthy aging J Neurosci 29 2009 15223 15231
201. S. Burgmans, M.P. van Boxtel, E.F. Vuurman, F. Smeets, E.H. Gronenschild, and H.B. Uylings The prevalence of cortical gray matter atrophy may be overestimated in the healthy aging brain, Neuropsychology 23 2009 541 550
202. A.M. Fjell, L.T. Westlye, T. Espeseth, I. Reinvang, A.M. Dale, and D. Holland Cortical gray matter atrophy in healthy aging cannot be explained by undetected incipient cognitive disorders: a comment on Burgmans, et al. (2009) Neuropsychology 24 2010 258 263 discussion 264-6
203. E.A. Murphy, D. Holland, M. Donohue, L.K. McEvoy, D.J. Hagler Jr., and A.M. Dale Six-month atrophy in MTL structures is associated with subsequent memory decline in elderly controls Neuroimage 53 2010 1310 1317
204. J. Nettiksimmons, D. Harvey, J. Brewer, O. Carmichael, C. Decarli, and C.R. Jack Jr. Subtypes based on cerebrospinal fluid and magnetic resonance imaging markers in normal elderly predict cognitive decline Neurobiol Aging 31 2010 1419 1428
205. A.M. Fjell, K.B. Walhovd, C. Fennema-Notestine, L.K. McEvoy, D.J. Hagler, and D. Holland Brain Atrophy in Healthy Aging Is Related to CSF Levels of A{beta}1-42 Cereb Cortex 20 2010 2069 2079
206. E.C. Mormino, J.T. Kluth, C.M. Madison, G.D. Rabinovici, S.L. Baker, and B.L. Miller Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects Brain 132 (Pt 5) 2009 1310 1323
207. G.C. Chiang, P.S. Insel, D. Tosun, N. Schuff, D. Truran-Sacrey, and S.T. Raptentsetsang Hippocampal atrophy rates and CSF biomarkers in elderly APOE2 normal subjects Neurology 75 2010 1976 1981
208. M. Fan, B. Liu, Y. Zhou, X. Zhen, C. Xu, and T. Jiang Cortical thickness is associated with different apolipoprotein E genotypes in healthy elderly adults Neurosci Lett 479 2010 332 336
209. A.J. Ho, J.L. Stein, X. Hua, S. Lee, D.P. Hibar, and A.D. Leow A commonly carried allele of the obesity-related FTO gene is associated with reduced brain volume in the healthy elderly Proc Natl Acad Sci USA 107 2010 8404 8409
210. L.M. Rimol, I. Agartz, S. Djurovic, A.A. Brown, J.C. Roddey, and A.K. Kahler Sex-dependent association of common variants of microcephaly genes with brain structure Proc Natl Acad Sci USA 107 2010 384 388
211. A.H. Joyner, J.C. Roddey, C.S. Bloss, T.E. Bakken, L.M. Rimol, and I. Melle A common MECP2 haplotype associates with reduced cortical surface area in humans in two independent populations Proc Natl Acad Sci USA 106 2009 15483 15488
212. G.B. Frisoni Alzheimer's disease neuroimaging Initiative in Europe Alzheimers Dement 6 2010 280 285
213. G.B. Frisoni, W.J. Henneman, M.W. Weiner, P. Scheltens, B. Vellas, and E. Reynish The pilot European Alzheimer's Disease Neuroimaging Initiative of the European Alzheimer's Disease Consortium, Alzheimers Dement 4 2008 255 264 (Pubitemid 351876326)
214. K. Buerger, G. Frisoni, O. Uspenskaya, M. Ewers, H. Zetterberg, and C. Geroldi Validation of Alzheimer's disease CSF and plasma biological markers: the multicentre reliability study of the pilot European Alzheimer's Disease Neuroimaging Initiative (E-ADNI) Exp Gerontol 44 2009 579 585
215. N. Mattsson, U. Andreasson, S. Persson, H. Arai, S.D. Batish, and S. Bernardini The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers Alzheimers Dement 7 2011 386 395.e6
216. G.B. Frisoni, and C.R. Jack Harmonization of magnetic resonance-based manual hippocampal segmentation: a mandatory step for wide clinical use Alzheimers Dement 7 2011 171 174
217. K.A. Ellis, C.C. Rowe, V.L. Villemagne, R.N. Martins, C.L. Masters, and O. Salvado Addressing population aging and Alzheimer's disease through the Australian imaging biomarkers and lifestyle study: collaboration with the Alzheimer's Disease Neuroimaging Initiative Alzheimers Dement 6 2010 291 296
218. C.C. Rowe, K.A. Ellis, M. Rimajova, P. Bourgeat, K.E. Pike, and G. Jones Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging Neurobiol Aging 31 2010 1275 1283
219. H. Fukuyama Neuroimaging in mild cognitive impairment, [in Japanese] Rinsho Shinkeigaku 46 2006 791 794 (Pubitemid 46623850)
220. T. Iwatsubo Japanese ADNI: present status and future Alzheimers Dement 6 2010 297 299
221. H. Arai Alzheimer's disease neuroimaging initiative and mild cognitive impairment, [in Japanese] Rinsho Shinkeigaku 47 2007 905 907 (Pubitemid 351152329)
222. Y. Ihara Overview on Alzheimer's disease, [in Japanese] Rinsho Shinkeigaku 47 2007 902 904
223. S. Murayam, and Y. Saito Neuropathology of mild cognitive impairment Alzheimer's disease, [in Japanese] Rinsho Shinkeigaku 47 2007 912 914 (Pubitemid 351152331)
224. H. Arai, N. Okamura, K. Furukawa, and Y. Kudo Geriatric medicine, Japanese Alzheimer's disease neuroimaging initiative and biomarker development Tohoku J Exp Med 221 2010 87 95
225. Li Y, Wang Y, Wu G, Shi F, Zhou L, Lin W, et al. Discriminant analysis of longitudinal cortical thickness changes in Alzheimer's disease using dynamic and network features. Neurobiol Aging (in press).
226. Heckemann RA, et al. Automatic morphometry in Alzheimer's disease and mild cognitive impairment. Neuroimage 2011;56:2024-37.
227. Romero K, Corrigan B, Neville J, Kopko S, Cantillon M., Striving for an integrated drug development process for neurodegeneration: The Coalition Against Major Diseases. Neurodegen Dis Manage 2011;1:379-85.
228. Kang JH, Vanderstichele H, Trojanowski JQ, Shaw LM. Simultaneous analysis of cerebrospinal fluid biomarkers using microsphere-based xMAP multiplex technology for early detection of Alzheimer's disease. Methods 2012;56:484-93.
229. Li X, Long X, Laurienti P, Wyatt C. Registration of images with varying topology using embedded maps. IEEE Trans Med Imaging 2012;31:749-65.
230. Leung KK, Ridgway GR, Ourselin S, Fox NC. Consistent multi-time-point brain atrophy estimation from the boundary shift integral. Neuroimage 2012;59:3995-4005.
231. Lotjonen J, Wolz R, Koikkalainen J, Julkunen V, Thurfjell L, Lundqvist R, et al. Fast and robust extraction of hippocampus from MR images for diagnostics of Alzheimer's disease. Neuroimage 2011;56:185-96.
232. Pachauri D, Hinrichs C, Chung MK, Johnson SC, Singh V. Topology-based kernels with application to inference problems in Alzheimer's disease. IEEE Trans Med Imaging 2011;30:1760-70.
233. Cardoso MJ, Clarkson MJ, Ridgway GR, Modat M, Fox NC, Ourselin S. LoAd: a locally adaptive cortical segmentation algorithm. Neuroimage 2011;56:1386-97.
234. Koikkalainen J, Lotjonen J, Thurfjell L, Rueckert D, Waldemar G, Soininen H. Multi-template tensor-based morphometry: application to analysis of Alzheimer's disease. Neuroimage 2011;56:1134-44.
235. Cover KS, van Schijndel RA, van Dijk BW, Redolfi A, Knol DL, Frisoni GB, et al. Assessing the reproducibility of the SienaX and Siena brain atrophy measures using the ADNI back-to-back MP-RAGE MRI scans. Psychiatry Res 2011;193:182-90.
236. Shen KK, Fripp J, Meriaudeau F, Chetelat G, Salvado O, Bourgeat P. Detecting global and local hippocampal shape changes in Alzheimer's disease using statistical shape models. Neuroimage 2012;59:2155-66.
237. Cho Y, Seong JK, Jeong Y, Shin SY. Individual subject classification for Alzheimer's disease based on incremental learning using a spatial frequency representation of cortical thickness data. Neuroimage 2012;59:2217-30.
238. Abdulkadir A, Mortamet B, Vemuri P, Jack CR, Jr., Krueger G, Kloppel S. Effects of hardware heterogeneity on the performance of SVM Alzheimer's disease classifier. Neuroimage 2011;58:785-92.
239. Zhang, D. and D. Shen, Predicting future clinical changes of MCI patients using longitudinal and multimodal biomarkers. PLoS One, 2012. 7: e33182.
240. Aksu Y, Miller DJ, Kesidis G, Bigler DC, Yang QX. An MRI-derived definition of MCI-to-AD conversion for long-term, automatic prognosis of MCI patients. PLoS One, 2011. 6: e25074.
241. Casanova R, Whitlow CT, Wagner B, Williamson J, Shumaker SA, Maldjian JA, et al. High dimensional classification of structural MRI Alzheimer's disease data based on large scale regularization. Front Neuroinform, 2011. 5: p. 22.
242. Clark DG, Residual vectors for Alzheimer disease diagnosis and prognostication. Brain Behav 2011;1:142-52.
243. Markiewicz PJ, Matthews JC, Declerck J, Herholz K. Robustness of multivariate image analysis assessed by resampling techniques and applied to FDG-PET scans of patients with Alzheimer's disease. Neuroimage 2009;46:472-85.
244. Markiewicz PJ, Matthews JC, Declerck J, Herholz K. Verification of predicted robustness and accuracy of multivariate analysis. Neuroimage 2011;56:1382-85.
245. Rasmussen JM, Lakatos A, van Erp TG, Kruggel F, Keator DB, Fallon JT, et al. Empirical derivation of the reference region for computing diagnostic sensitive (1)fluorodeoxyglucose ratios in Alzheimer's disease based on the ADNI sample. Biochim Biophys Acta 2012;1822:457-66.
246. Tractenberg RE and R.H. Pietrzak, Intra-individual variability in Alzheimer's disease and cognitive aging: definitions, context, and effect sizes. PLoS One, 2011. 6: e16973.
247. Hinrichs C, Singh V, Xu G, Johnson SC. Predictive markers for AD in a multi-modality framework: an analysis of MCI progression in the ADNI population. Neuroimage 2011;55:574-89.
248. Padilla P, Lopez M, Gorriz JM, Ramirez J, Salas-Gonzalez D, Alvarez I. NMF-SVM based CAD tool applied to functional brain images for the diagnosis of Alzheimer's disease. IEEE Trans Med Imaging 2012;31:207-16.
249. Zhang D, Wang Y, Zhou L, Yuan H, Shen D. Multimodal classification of Alzheimer's disease and mild cognitive impairment. Neuroimage 2011;55:856-67.
250. Zhang D. and D. Shen, Multi-modal multi-task learning for joint prediction of multiple regression and classification variables in Alzheimer's disease. Neuroimage 2012;59:895-907.
251. Wang H, Nie F, Huang H, Risacher S, and Saykin A, Ding C, Shen L, ADNI, Sparse Multi-Task Regression and Feature Selection to Identify Brain Imaging Predictors for Memory Performance. IEEE Conference on Computer Vision, 2011: 557-62.
252. Mattila J, Koikkalainen J, Virkki A, Simonsen A, van Gils M, Waldemar G, et al. A disease state fingerprint for evaluation of Alzheimer's disease. J Alzheimers Dis 2011;27:163-76.
253. Soininen H, Mattila J, Koikkalainen J, van Gils M, Hviid Simonsen A, Waldemar G, et al. Software tool for improved prediction of Alzheimer's disease. Neurodegener Dis 2012;10:149-52.
254. Mayeux R. and N. Schupf, Blood-based biomarkers for Alzheimer's disease: plasma Abeta40 and Abeta42, and genetic variants. Neurobiol Aging, 2011. 32 Suppl 1: S10-9.
255. O'Bryant SE, Xiao G, Barber R, Huebinger R, Wilhelmsen K, Edwards M, et al. A blood-based screening tool for Alzheimer's disease that spans serum and plasma: findings from TARC and ADNI. PLoS One, 2011. 6: e28092.
256. Figurski MJ, Waligorska T, Toledo J, Vanderstichele H, Korecka M, Lee VM, et al. Improved protocol for measurement of plasma beta-amyloid in longitudinal evaluation of Alzheimer's Disease Neuroimaging Initiative study patients. Alzheimers Dement, 2012. 8): 250-60.
257. Toledo JB, Vanderstichele H, Figurski M, Aisen PS, Petersen RC, Weiner MW, et al. Factors affecting Abeta plasma levels and their utility as biomarkers in ADNI. Acta Neuropathol 2011;122:401-13.
258. Rissman RA, Trojanowski JQ, Shaw LM, Aisen PS. Longitudinal plasma amyloid beta as a biomarker of Alzheimer's disease. J Neural Transm 2012;119:843-50.
259. Soares HD, Potter WZ, Pickering E, Kuhn M, Immermann FW, Shera DM, et al. Plasma Biomarkers Associated With the Apolipoprotein E Genotype and Alzheimer Disease. Arch Neurol, 2012: 1-8.
260. Hu WT, Holtzman DM, Fagan AM, Shaw LM, Perrin R, Arnold SE, et al. Plasma multianalyte profiling in mild cognitive impairment and Alzheimer disease. Neurology, 2012.
261. Dukart J., M.L. Schroeter, and K. Mueller, Age correction in dementia-matching to a healthy brain. PLoS One, 2011. 6: e22193.
262. Samtani MN, Farnum M, Lobanov V, Yang E, Raghavan N, Dibernardo A, et al. An improved model for disease progression in patients from the Alzheimer's disease neuroimaging initiative. J Clin Pharmacol 2012;52:629-44.
263. Meda SA, Narayanan B, Liu J, Perrone-Bizzozero NI, Stevens MC, Calhoun VD, et al. A large scale multivariate parallel ICA method reveals novel imaging-genetic relationships for Alzheimer's disease in the ADNI cohort. Neuroimage 2012;60:1608-21.
264. Wang H, Nie F, Huang H, Kim S, Nho K, Risacher SL, et al. Identifying quantitative trait loci via group-sparse multitask regression and feature selection: an imaging genetics study of the ADNI cohort. Bioinformatics 2012;28:229-37.
265. Spiegel R, Berres M, Miserez AR, Monsch AU. For debate: substituting placebo controls in long-term Alzheimer's prevention trials. Alzheimers Res Ther, 2011. 3(): p. 9.
266. Donohue MC, Gamst AC, Thomas RG, Xu R, Beckett L, Petersen RC, et al. The relative efficiency of time-to-threshold and rate of change in longitudinal data. Contemp Clin Trials 2011;32:685-93.
267. Greene SJ and R.J. Killiany, Hippocampal subregions are differentially affected in the progression to Alzheimer's disease. Anat Rec (Hoboken) 2012;295:132-40.
268. Spampinato MV, Rumboldt Z, Hosker RJ, Mintzer JE. Apolipoprotein E and gray matter volume loss in patients with mild cognitive impairment and Alzheimer disease. Radiology 2011;258:843-52.
269. Skup M, Zhu H, Wang Y, Giovanello KS, Lin JA, Shen D, et al. Sex differences in grey matter atrophy patterns among AD and aMCI patients: results from ADNI. Neuroimage 2011;56:890-906.
270. Stricker NH, Chang YL, Fennema-Notestine C, Delano-Wood L, Salmon DP, Bondi MW, et al. Distinct profiles of brain and cognitive changes in the very old with Alzheimer disease. Neurology 2011;77:713-21.
271. Poulin SP, Dautoff R, Morris JC, Barrett LF, Dickerson BC. Amygdala atrophy is prominent in early Alzheimer's disease and relates to symptom severity. Psychiatry Res 2011;194:7-13.
272. Zhang N, Song X, Zhang Y, Chen W, D'Arcy RC, Darvesh S, et al. An MRI brain atrophy and lesion index to assess the progression of structural changes in Alzheimer's disease, mild cognitive impairment, and normal aging: a follow-up study. J Alzheimers Dis, 2011. 26 Suppl 3: 359-67.
273. Rajagopalan P, Hua X, Toga AW, Jack CR Jr, Weiner MW, Thompson PM, Homocysteine effects on brain volumes mapped in 732 elderly individuals. Neuroreport 2011;22:391-5.
274. Brown PJ, Devanand DP, Liu X, Caccappolo E. Functional impairment in elderly patients with mild cognitive impairment and mild Alzheimer disease. Arch Gen Psychiatry 2011;68:617-26.
275. Bonner-Jackson A., O. Okonkwo, and G. Tremont, Apolipoprotein E epsilon2 and functional decline in amnestic mild cognitive impairment and Alzheimer disease. Am J Geriatr Psychiatry 2012;20:584-93.
276. Marshall GA, Olson LE, Frey MT, Maye J, Becker JA, Rentz DM. Instrumental activities of daily living impairment is associated with increased amyloid burden. Dement Geriatr Cogn Disord 2011;31:443-50.
277. Marshall GA, Rentz DM, Frey MT, Locascio JJ, Johnson KA, Sperling RA. Executive function and instrumental activities of daily living in mild cognitive impairment and Alzheimer's disease. Alzheimers Dement 2011;7:300-8.
278. Vemuri P, Weigand SD, Przybelski SA, Knopman DS, Smith GE, Trojanowski JQ, et al. Cognitive reserve and Alzheimer's disease biomarkers are independent determinants of cognition. Brain, 2011. 134(Pt 5): 1479-92.
279. Ewers M, Schmitz S, Hansson O, Walsh C, Fitzpatrick A, Bennett D, et al. Body mass index is associated with biological CSF markers of core brain pathology of Alzheimer's disease. Neurobiol Aging 2012;33:1599-608.
280. Vidoni ED, Townley RA, Honea RA, Burns JM. Alzheimer disease biomarkers are associated with body mass index. Neurology 2011;77:1913-20.
281. Lo RY, Hubbard AE, Shaw LM, Trojanowski JQ, Petersen RC, Aisen PS, et al. Longitudinal change of biomarkers in cognitive decline. Arch Neurol 2011;68:1257-66.
282. Jack CR, Jr, Vemuri P, Wiste HJ, Weigand SD, Aisen PS, Trojanowski JQ, et al. Evidence for ordering of Alzheimer disease biomarkers. Arch Neurol 2011;68:1526-35.
283. Chincarini A, Bosco P, Calvini P, Gemme G, Esposito M, Olivieri C, et al. Local MRI analysis approach in the diagnosis of early and prodromal Alzheimer's disease. Neuroimage 2011;58:469-80.
284. Wolz R, Julkunen V, Koikkalainen J, Niskanen E, Zhang DP, Rueckert D, et al. Multi-method analysis of MRI images in early diagnostics of Alzheimer's disease. PLoS One, 2011. 6: e25446.
285. Gray KR, Wolz R, Heckemann RA, Aljabar P, Hammers A, Rueckert D. Multi-region analysis of longitudinal FDG-PET for the classification of Alzheimer's disease. Neuroimage 2012;60:221-9.
286. Johnstone D, Milward EA, Berretta R, Moscato P. Multivariate protein signatures of pre-clinical Alzheimer's disease in the Alzheimer's disease neuroimaging initiative (ADNI) plasma proteome dataset. PLoS One, 2012. 7: e34341.
287. Cui Y, Liu B, Luo S, Zhen X, Fan M, Liu T, et al. Identification of conversion from mild cognitive impairment to Alzheimer's disease using multivariate predictors. PLoS One, 2011. 6: e21896.
288. Schmand B., P. Eikelenboom, and W.A. van Gool, Value of neuropsychological tests, neuroimaging, and biomarkers for diagnosing Alzheimer's disease in younger and older age cohorts. J Am Geriatr Soc 2011;59:1705-10.
289. Dickerson BC and D.A. Wolk, MRI cortical thickness biomarker predicts AD-like CSF and cognitive decline in normal adults. Neurology 2012;78:84-90.
290. Chiang GC, Insel PS, Tosun D, Schuff N, Truran-Sacrey D, Raptentsetsang S, et al. Identifying cognitively healthy elderly individuals with subsequent memory decline by using automated MR temporoparietal volumes. Radiology 2011;259:844-51.
291. Herholz K, Westwood S, Haense C, Dunn G. Evaluation of a calibrated (18)F-FDG PET score as a biomarker for progression in Alzheimer disease and mild cognitive impairment. J Nucl Med 2011;52:1218-26.
292. Mackin RS, Insel P, Aisen PS, Geda YE, Weiner MW. Longitudinal stability of subsyndromal symptoms of depression in individuals with mild cognitive impairment: relationship to conversion to dementia after 3 years. Int J Geriatr Psychiatry 2012;27:355-63.
293. Lee GJ, Lu PH, Hua X, Lee S, Wu S, Nguyen K, et al. Depressive symptoms in mild cognitive impairment predict greater atrophy in Alzheimer's disease-related regions. Biol Psychiatry, 2012. 71(: 814-21.
294. Gomar JJ, Bobes-Bascaran MT, Conejero-Goldberg C, Davies P, Goldberg TE. Utility of combinations of biomarkers, cognitive markers, and risk factors to predict conversion from mild cognitive impairment to Alzheimer disease in patients in the Alzheimer's disease neuroimaging initiative. Arch Gen Psychiatry 2011;68:961-9.
295. Heister D, Brewer JB, Magda S, Blennow K, McEvoy LK. Predicting MCI outcome with clinically available MRI and CSF biomarkers. Neurology 2011;77:1619-28.
296. Devanand DP, Liu X, Brown PJ, Huey ED, Stern Y, Pelton GH. A two-study comparison of clinical and MRI markers of transition from mild cognitive impairment to Alzheimer's disease. Int J Alzheimers Dis, 2012. 2012: p. 483469.
297. Holland D., L.K. McEvoy, and A.M. Dale, Unbiased comparison of sample size estimates from longitudinal structural measures in ADNI. Hum Brain Mapp, 2012. 33(: 2586-602.
298. Schrag A. and J.M. Schott, What is the clinically relevant change on the ADAS-Cog? J Neurol Neurosurg Psychiatry 2012;83:171-3.
299. Henley DB, Sundell KL, Sethuraman G, Siemers ER. Safety profile of Alzheimer's disease populations in Alzheimer's Disease Neuroimaging Initiative and other 18-month studies. Alzheimers Dement 2012;8:407-16.
300. Thompson WK, J. Hallmayer, and R. O'Hara, Design considerations for characterizing psychiatric trajectories across the lifespan: application to effects of APOE-epsilon4 on cerebral cortical thickness in Alzheimer's disease. Am J Psychiatry 2011;168:894-903.
301. Erten-Lyons D, Wilmot B, Anur P, McWeeney S, Westaway SK, Silbert L, et al. Microcephaly genes and risk of late-onset Alzheimer disease. Alzheimer Dis Assoc Disord 2011;25:276-82.
302. Murphy EA, Roddey JC, McEvoy LK, Holland D, Hagler DJ, Jr., Dale AM, et al. CETP polymorphisms associate with brain structure, atrophy rate, and Alzheimer's disease risk in an APOE-dependent manner. Brain Imaging Behav 2012;6:16-26.
303. Xu C, Wang Z, Fan M, Liu B, Song M, Zhen X, et al. Effects of BDNF Val66Met polymorphism on brain metabolism in Alzheimer's disease. Neuroreport 2010;21:802-7.
304. Kamboh MI, Barmada MM, Demirci FY, Minster RL, Carrasquillo MM, Pankratz VS, et al. Genome-wide association analysis of age-at-onset in Alzheimer's disease. Mol Psychiatry 2012;17:1340-46.
305. Hibar DP, Stein JL, Kohannim O, Jahanshad N, Saykin AJ, Shen L, et al. Voxelwise gene-wide association study (vGeneWAS): multivariate gene-based association testing in 731 elderly subjects. Neuroimage 2011;56:1875-91.
306. Schott JM, Using CSF biomarkers to replicate genetic associations in Alzheimer's disease. Neurobiol Aging, 2012. 33(7): 1486.e9-15.
307. Swaminathan S, Shen L, Risacher SL, Yoder KK, West JD, Kim S, et al. Amyloid pathway-based candidate gene analysis of [(11)C]PiB-PET in the Alzheimer's Disease Neuroimaging Initiative (ADNI) cohort. Brain Imaging Behav 2012;6:1-15.
308. Hu X, Pickering E, Liu YC, Hall S, Fournier H, Katz E, et al. Meta-analysis for genome-wide association study identifies multiple variants at the BIN1 locus associated with late-onset Alzheimer's disease. PLoS One, 2011. 6: e16616.
309. Antunez C, Boada M, Gonzalez-Perez A, Gayan J, Ramirez-Lorca R, Marin J, et al. Genetic association of complement receptor 1 polymorphism rs3818361 in Alzheimer's disease. Alzheimers Dement, 2011. 7: e124-9.
310. Cruchaga C, Nowotny P, Kauwe JS, Ridge PG, Mayo K, Bertelsen S, et al. Association and expression analyses with single-nucleotide polymorphisms in TOMM40 in Alzheimer disease. Arch Neurol 2011;68:1013-19.
311. Antunez C, Boada M, Gonzalez-Perez A, Gayan J, Ramirez-Lorca R, Marin J, et al. The membrane-spanning 4-domains, subfamily A (MS4A) gene cluster contains a common variant associated with Alzheimer's disease. Genome Med, 2011. 3: p. 33.
312. Kauwe JS, Cruchaga C, Karch CM, Sadler B, Lee M, Mayo K, et al. Fine mapping of genetic variants in BIN1, CLU, CR1 and PICALM for association with cerebrospinal fluid biomarkers for Alzheimer's disease. PLoS One, 2011. 6: e15918.
313. Alexopoulos P, Guo LH, Kratzer M, Westerteicher C, Kurz A, Perneczky R. Impact of SORL1 single nucleotide polymorphisms on Alzheimer's disease cerebrospinal fluid markers. Dement Geriatr Cogn Disord 2011;32:164-70.
314. Swaminathan S, Kim S, Shen L, Risacher SL, Foroud T, Pankratz N, et al. Genomic Copy Number Analysis in Alzheimer's Disease and Mild Cognitive Impairment: An ADNI Study. Int J Alzheimers Dis, 2011. 2011: p. 729478.
315. Swaminathan S, Shen L, Kim S, Inlow M, West JD, Faber KM, et al. Analysis of copy number variation in Alzheimer's disease: the NIALOAD/ NCRAD Family Study. Curr Alzheimer Res 2012;9:801-14.
316. Stein JL, Hibar DP, Madsen SK, Khamis M, McMahon KL, de Zubicaray GI, et al. Discovery and replication of dopamine-related gene effects on caudate volume in young and elderly populations (N=1198) using genome-wide search. Mol Psychiatry 2011;16:927-37, 881.
317. Bakken TE, Roddey JC, Djurovic S, Akshoomoff N, Amaral DG, Bloss CS, et al. Association of common genetic variants in GPCPD1 with scaling of visual cortical surface area in humans. Proc Natl Acad Sci U S A, 2012. 109(: 3985-90.
318. Yesavage JA, Noda A, Hernandez B, Friedman L, Cheng JJ, Tinklenberg JR, et al. Circadian clock gene polymorphisms and sleep-wake disturbance in Alzheimer disease. Am J Geriatr Psychiatry 2011;19:635-43.
319. Bakken TE, A.M. Dale, and N.J. Schork, A geographic cline of skull and brain morphology among individuals of European Ancestry. Hum Hered 2011;72:35-44.
320. David R, Friedman L, Mulin E, Noda A, Le Duff F, Kennedy Q, et al. Lack of Association Between COMT Polymorphisms and Apathy in Alzheimer's Disease. J Alzheimers Dis 2011;27:155-61.
321. Hibar DP, Kohannim O, Stein JL, Chiang MC, Thompson PM. Multilocus genetic analysis of brain images. Front Genet, 2011. 2: p. 73.
322. Nho K, Shen L, Kim S, Swaminathan S, Risacher SL, Saykin AJ. The effect of reference panels and software tools on genotype imputation. AMIA Annu Symp Proc 2011;2011:1013-18.
323. Wan J, Kim S, Inlow M, Nho K, Swaminathan S, Risacher SL, et al. Hippocampal surface mapping of genetic risk factors in AD via sparse learning models. Med Image Comput Comput Assist Interv, 2011. 14(Pt 2): 376-83.
324. Cruchaga C, Kauwe JS, Nowotny P, Bales K, Pickering EH, Mayo K, et al. Cerebrospinal fluid APOE levels: an endophenotype for genetic studies for Alzheimer's disease. Hum Mol Genet 2012;21:4558-71.
325. Damoiseaux JS, Seeley WW, Zhou J, Shirer WR, Coppola G, Karydas A, et al. Gender modulates the APOE epsilon4 effect in healthy older adults: convergent evidence from functional brain connectivity and spinal fluid tau levels. J Neurosci 2012;32:8254-62.
326. De Jager PL, Shulman JM, Chibnik LB, Keenan BT, Raj T, Wilson RS, et al. A genome-wide scan for common variants affecting the rate of age-related cognitive decline. Neurobiol Aging 2012;33:1017.e1-15.
327. Ge T, Feng J, Hibar DP, Thompson PM, Nichols TE. Increasing power for voxel-wise genome-wide association studies: the random field theory, least square kernel machines and fast permutation procedures. Neuroimage 2012;63:858-73.
328. Hibar DP, Stein JL, Ryles AB, Kohannim O, Jahanshad N, Medland SE, et al. Genome-wide association identifies genetic variants associated with lentiform nucleus volume in N = 1345 young and elderly subjects. Brain Imaging Behav, 2012.
329. Jahanshad N, Kohannim O, Hibar DP, Stein JL, McMahon KL, de Zubicaray GI, et al. Brain structure in healthy adults is related to serum transferrin and the H63D polymorphism in the HFE gene. Proc Natl Acad Sci U S A, 2012. 109: E851-9.
330. Keenan BT, Shulman JM, Chibnik LB, Raj T, Tran D, Sabuncu MR, et al. A coding variant in CR1 interacts with APOE-epsilon4 to influence cognitive decline. Hum Mol Genet 2012;21:2377-88.
331. Kohannim O, Hibar DP, Jahanshad N, Stein JL, Hua X, Toga AW, et al. Predicting Temporal Lobe Volume on Mri from Genotypes Using L(1)-L(2) Regularized Regression. Proc IEEE Int Symp Biomed Imaging, 2012: 1160-63.
332. Kohannim O, Hibar DP, Stein JL, Jahanshad N, Hua X, Rajagopalan P, et al. Discovery and Replication of Gene Influences on Brain Structure Using LASSO Regression. Front Neurosci, 2012. 6: p. 115.
333. Lourdusamy A, Newhouse S, Lunnon K, Proitsi P, Powell J, Hodges A, et al. Identification of cis-regulatory variation influencing protein abundance levels in human plasma. Hum Mol Genet 2012;21:3719-26.
334. Mattila J, Koikkalainen J, Virkki A, van Gils M, Lotjonen J. Design and application of a generic clinical decision support system for multiscale data. IEEE Trans Biomed Eng 2012;59:234-40.
335. Melville SA, Buros J, Parrado AR, Vardarajan B, Logue MW, Shen L, et al. Multiple loci influencing hippocampal degeneration identified by genome scan. Ann Neurol 2012;72:65-75.
336. Ramanan VK, Kim S, Holohan K, Shen L, Nho K, Risacher SL, et al. Genome-wide pathway analysis of memory impairment in the Alzheimer's Disease Neuroimaging Initiative (ADNI) cohort implicates gene candidates, canonical pathways, and networks. Brain Imaging Behav, 2012;6:634-48.
337. Mukherjee S, Kim S, Gibbons LE, Nho K, Risacher SL, Glymour MM, et al. Genetic architecture of resilience of executive functioning. Brain Imaging Behav, 2012;6:621-33.
338. Silver M, Janousova E, Hua X, Thompson PM, Montana G. Identification of gene pathways implicated in Alzheimer's disease using longitudinal imaging phenotypes with sparse regression. Neuroimage 2012;63:1681-94.
339. Silver M. and G. Montana, Fast identification of biological pathways associated with a quantitative trait using group lasso with overlaps. Stat Appl Genet Mol Biol, 2012. 11: Article 7.
340. Stein JL, Medland SE, Vasquez AA, Hibar DP, Senstad RE, Winkler AM, et al. Identification of common variants associated with human hippocampal and intracranial volumes. Nat Genet 2012;44:552-61.
341. Thambisetty M, An Y, Nalls M, Sojkova J, Swaminathan S, Zhou Y, et al. Effect of Complement CR1 on Brain Amyloid Burden During Aging and Its Modification byAPOEGenotype. Biol Psychiatry, 2012; 73:334-41.
342. Vounou M, Janousova E, Wolz R, Stein JL, Thompson PM, Rueckert D, et al. Sparse reduced-rank regression detects genetic associations with voxel-wise longitudinal phenotypes in Alzheimer's disease. Neuroimage 2012;60:700-16.
343. Wang H, Nie F, Huang H, Risacher SL, Saykin AJ, Shen L. Identifying disease sensitive and quantitative trait-relevant biomarkers from multidimensional heterogeneous imaging genetics data via sparse multimodal multitask learning. Bioinformatics, 2012. 28: i127-36.
344. Wang H, Nie F, Huang H, Yan J, Kim S, Nho K, et al. From phenotype to genotype: an association study of longitudinal phenotypic markers to Alzheimer's disease relevant SNPs. Bioinformatics, 2012. 28i619-25.
345. Weiner MW, Veitch DP, Aisen PS, Beckett LA, Cairns NJ, Green RC, et al. The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception. Alzheimers Dement, 2012. 8(1 Suppl): S1-68.
346. Ye J, Farnum M, Yang E, Verbeeck R, Lobanov V, Raghavan N, et al. Sparse learning and stability selection for predicting MCI to AD conversion using baseline ADNI data. BMC Neurol, 2012. 12: p. 46.
347. Westman E, Simmons A, Muehlboeck JS, Mecocci P, Vellas B, Tsolaki M, et al. AddNeuroMed and ADNI: similar patterns of Alzheimer's atrophy and automated MRI classification accuracy in Europe and North America. Neuroimage 2011;58:818-28.
348. Cuingnet R, Rosso C, Chupin M, Lehericy S, Dormont D, Benali H, et al. Spatial regularization of SVM for the detection of diffusion alterations associated with stroke outcome. Med Image Anal 2011;15:729-37.
349. Jennings JR, Mendelson DN, Muldoon MF, Ryan CM, Gianaros PJ, Raz N, et al. Regional grey matter shrinks in hypertensive individuals despite successful lowering of blood pressure. J Hum Hypertens 2012;26:295-305.